Back to Archived News
US Patent Covering Amplification Consumables Granted to Enigma Diagnostics Limited
Monday, April 19, 2010
Oxford, England & San Diego, CA -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments. The consumables incorporate a thermally conducting layer and reaction wells in combination with a reaction mixture and a blocking agent. Enigma Diagnostics Ltd is the exclusive licensee of this patent from the UK Defence Science Technology Laboratory.
This is the most recent patent to issue in Enigma's expanding portfolio of over 300 patents and patent applications. This portfolio includes patents relating to intelligent sample preparation consumables and novel amplification technologies for current and 'next generation' molecular diagnostic systems and sample preparation devices. Enigma continues to expand its worldwide licensing programme and awareness of its broadly applicable and important IP portfolio which now includes this US patent.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of-care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialisation of real-time PCR instruments, and from Roche Molecular Systems to practise HybProbe real-time PCR chemistry for human and veterinary in vitro diagnostics. Enigma's in-house RandD activities have generated a portfolio of worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit www.enigmadiagnostics.com
Back to Archived News
